Huajing Wang

Construction of a home-based dietary self-management intervention program for maintenance hemodialysis patients based on the IKAP collaborative care model

Huajing Wang, X Y Zhou, H Zhang, Jieling Zhou et autres

Effective dietary self-management behaviors can mitigate complications, enhance quality of life, and prolong survival in patients undergoing maintenance hemodialysis (MHD); however, factors inherent to both the dialysis process and the underlying disease often result in poor adherence to prescribed treatment diets and …

cn (code pays fourni par la source)

Additional file 1 of Humanized biparatopic nanobody-based CAR-T cells overcome antigen-heterogeneity in multiple myeloma

Jincai Zhou, Kai Wu, Bixia Lei, Xinran Luo et autres

Supplementary material 1

Additional file 1 of Humanized biparatopic nanobody-based CAR-T cells overcome antigen-heterogeneity in multiple myeloma

Jincai Zhou, Kai Wu, Bixia Lei, Xinran Luo et autres

Supplementary material 1

Nitrogen inhibitors reduce cadmium accumulation in rice by modulating cadmium sequestration in Fe-Mn plaque andenhancing root antioxidant activity

Shen Zheng, Chao Xu, Daoyou Huang, Huajing Wang et autres

cn (code pays fourni par la source)

A Pilot Study on Non-Invasively Predicting Embryo Implantation via SERS Metabolic Profiling of Extracellular Vesicles

Jiangtian Li, Erqing Huang, Xiaofang Ding, Xiaoli Wang et autres

cn (code pays fourni par la source)

Cadmium Availability in a Soil-Rice System Receiving Four Consecutive Seasons of Straw Removal

Jialin Zhang, Hanhua Zhu, Chao Xu, Shen Zheng et autres

cn (code pays fourni par la source)

Advancing liver cancer treatment with dual-targeting CAR-T therapy

Ze Yang, Chao Cheng, Zhongliang Li, Huajing Wang et autres

Chimeric antigen receptor (CAR)-T cell therapy targeting glypican-3 (GPC3) has shown promise in the treatment of hepatocellular carcinoma (HCC). However, the efficacy of CAR-T cells that focus solely on cell surface tumor-associated antigens is often limited. To overcome this challenge, we developed …

cn, mo (code pays fourni par la source)

MSLN and CLDN18.2 dual-target CAR-T therapy: Enhancing cancer treatment with improved efficacy and safety.

Shasha Yang, Kaichun Wu, Jiantao Wang, Zhongjun Shi et autres

e16381 Background: While CAR-T cell therapy has been highly successful in treating hematologic malignancies, its application to solid tumors remains challenging due to the unique complexities of these cancers. MSLN and CLDN18.2, which show limited expression in normal tissues but are over-expressed …

cn (code pays fourni par la source)

Abstract 6062: A novel bi-specific antibody targeting CD39 and PD-L1 for enhanced cancer immunotherapy

Ze Yang, Xiaopei Li, Zhongliang Li, Yongfa Chen et autres

Abstract While immune checkpoint inhibitors have revolutionized cancer treatment, there remains a significant unmet need for more potent strategies to bolster anti-tumor immunity. This study introduces OriA631-B, a pioneering bi-specific antibody designed to simultaneously engage CD39 and PD-L1. By disrupting both the …

cn (code pays fourni par la source)

Abstract 6094: Enhanced GPC3-chimeric antigen receptor T cells with secreted bi-specific CD39-PD-L1 antibody for improved liver cancer therapy

Zhongliang Li, Bing Liu, Huajing Wang, Ke He et autres

Abstract Glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T cell therapy shows promise for treating liver cancer. However, the immunosuppressive tumor microenvironment (TME), characterized by elevated levels of adenosine and PD-L1 expression, significantly hinders CAR T cell efficacy. We previously demonstrated that a …

cn (code pays fourni par la source)

Abstract 6019: AI-guided development of CAR-T drugs

Chao Cheng, Yanjun Ge, Ermin Xie, Huajing Wang et autres

Abstract Background: Chimeric Antigen Receptor T-Cell (CAR-T) therapy is an innovative cancer treatment that involves genetically engineering a patient’s T-cells to recognize and attack cancer cells.Artificial Intelligence (AI) is playing an increasingly important role in drug development, accelerating drug discovery, optimizing treatment …

cn (code pays fourni par la source)

Abstract 4805: Dual-target CAR-T strategy for MSLN and CLDN18.2: Advancing cancer treatment with superior efficacy and safety

Shasha Yang, Kai Wu, Zhongjun Shi, Jiantao Wang et autres

Abstract Background: CAR-T-cell therapy has achieved great success in the treatment of hematological malignancies. However, due to the characteristics of solid malignant tumors, CAR-T for solid tumors is still in the exploration stage. The restricted expression of MSLN and CLDN18.2 in normal …

cn (code pays fourni par la source)